{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000022","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.152978+00:00","generated_at":"2026-05-24T06:33:43.919542+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elicio Therapeutics appoints Preetam Shah as Chief Strategy and Financial Officer","bullets":["Preetam Shah appointed Chief Strategy and Financial Officer effective March 24, 2025; will become Principal Financial Officer and Principal Accounting Officer on April 1, 2025.","Annual base salary $480,000; target bonus of 40% of base; initial option grant equal to 1.2% of outstanding shares as of April 15, 2025, vesting over 4 years.","Shah previously served as CFO/CBO at Cidara Therapeutics (Sept 2021–Feb 2025) and CFO & Treasurer at Brainstorm Cell Therapeutics (Sept 2019–Aug 2021).","The company highlights upcoming Phase 2 AMPLIFY-7P disease-free survival interim analysis for cancer immunotherapy ELI-002."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000022","json":"https://secwatch.observer/filing/0001601485-25-000022.json","markdown":"https://secwatch.observer/filing/0001601485-25-000022.md","text":"https://secwatch.observer/filing/0001601485-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/0001601485-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/angn-20250321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:33:43.919542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"247ad298a7","claim":"Preetam Shah was appointed as Chief Strategy and Financial Officer at Elicio Therapeutics, Inc..","evidence_excerpt":"On March 21, 2025, Elicio Therapeutics, Inc. (the “Company”) appointed Preetam Shah, Ph.D., M.B.A., as the Company’s Chief Strategy and Financial Officer effective as of March 24, 2025 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/0001601485-25-000022-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy and Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}